INTRODUCTION
Aplastic anemia is a rare and potentially life threatening disorder that occurs because of immune-mediated destruction of hematopoietic stem and progenitor cells (HSC). Allogeneic bone marrow transplantation (BMT) is well established as curative treatment. However, patients may also have a response to immune suppressive therapy (IST). Although prospective randomized clinical trials have not been performed, studies have consistently shown a survival benefit for patients who underwent human leukocyte antigen (HLA)-identical sibling BMT [1 & , [2] [3] [4] [5] [6] . New insights into the genetic alterations that occur with bone marrow failure and the inferior outcome with rabbit antithymocyte globulin (ATG) as IST support the rationale for patients to proceed to allogeneic BMT as first-line treatment. With reduced toxicity conditioning regimens and optimization of the donor graft, the long-term outcome of HLA-matched unrelated donor (URD) BMT has significantly improved. The challenge for hematologists is to determine when to treat patients with severe aplastic anemia (SAA) with IST or HLAmatched URD BMT or HLA-haploidentical hematopoietic stem cell transplantation (HSCT). Recent data support the decision to proceed to URD BMT as first-line therapy for younger patients if an HLA-matched donor can be rapidly identified.
ETIOLOGY OF APLASTIC ANEMIA AND IMMUNE SUPPRESSIVE THERAPY
et al. [7] . Subsequently, cyclosporine (CSP) added to ATG achieved better responses [8] . In a randomized study conducted at the NIH, horse ATG was shown to be superior to rabbit ATG as first-line IST for SAA [9] . Unfortunately, horse ATG is not available in most countries outside the United States. Follow-up reports confirmed that rabbit ATGþCSP was significantly less effective than horse ATGþCSP as initial IST for aplastic anemia [10] [11] [12] . The responsiveness of aplastic anemia to IST is evidence for the immune-mediated pathophysiology of the disease [13] .
CLONAL HEMATOPOIESIS AND SOMATIC MUTATIONS IN ACQUIRED APLASTIC ANEMIA
For many years it has been recognized that a subset of patients with aplastic anemia treated with IST has clonal hematopoiesis and some eventually develop cytogenetic abnormalities that lead to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) [14] [15] [16] . With the development of high-throughput sequencing, the molecular basis of clonal hematopoiesis in aplastic anemia has been comprehensively assessed [ [20] . Another study found mutations in ASXL1 were associated with progression to MDS [21] . Using whole exome sequencing, one group reported somatic mutations in 73% of SAA patients, involving 51 genes, including PIGA, 6pUPD, and in signaling pathways STAT5B and CAMK2G [22 & ]. In summary, deep sequencing for commonly mutated MDS/AML genes may be useful to determine if patients with poor-prognosis somatic mutations should be referred for allogeneic BMT either prior to failure of IST or to prevent the subsequent progression to MDS/AML. Although patients with SAA who evolve to MDS/AML can be successfully treated with BMT, outcomes are inferior to BMT early after the diagnosis of SAA [23, 24] .
CYTOGENETIC ABNORMALITIES AFTER TREATMENT WITH THROMBOPOIETIN-MIMETICS
Eltrombopag, an oral thrombopoietin (TPO) receptor agonist, has been evaluated in refractory SAA patients who remained panyctopenic after IST. TPO receptor is present on HSCs and eltrombopag stimulates proliferation of residual HSCs. In a follow-up report of 43 SAA patients, the overall response rate to eltrombopag was 40% at 4 months. A small proportion of patients were able to discontinue eltrombopag with normal blood counts. However, 19% developed cytogenetic abnormalities including -7, a poor prognosis finding [25] . These results are similar to the observation that G-CSF treatment concurrent with IST increased the risk
KEY POINTS
Patients with SAA treated with IST acquire somatic mutations in myeloid cancer candidate genes at high frequency.
HLA-identical sibling BMT remains first-line treatment of SAA. Outcomes with HLA-identical sibling BMT are consistently superior to IST.
Bone marrow is the only acceptable stem cell source for first-time HLA-identical sibling and HLA-matched URD HSCT for SAA.
Due to improved outcomes with conditioning regimens consisting of fludarabine/low-dose cyclophosphamide/ low-dose total body irradiation, HLA-matched URD BMT can now be considered as first-line treatment for SAA in younger patients.
HLA-haploidentical family member HSCT with the posttransplant cyclophosphamide conditioning regimen has encouraging results and is considered second-line or third-line treatment after failure of IST if no HLAmatched donor is available.
of development of -7 abnormalities and progression to MDS/AML [26] [27] [28] .
Although IST may be effective in ameliorating the pancytopenia of aplastic anemia, the development of somatic mutations results in significant risk for evolution to MDS/AML. The new molecular findings of a relatively high incidence of acquired mutations in myeloid cancer genes support the rationale to proceed to allogeneic BMT as first-line treatment, if a suitable donor can be identified, because BMT offers the greatest potential for definitive curative therapy of SAA.
HUMAN LEUKOCYTE ANTIGEN-IDENTICAL SIBLING DONOR BONE MARROW TRANSPLANTATION
Although there had been a steady and impressive improvement in survival after HLA-identical sibling donor BMT, when several transplant centers began using G-CSF mobilized peripheral blood stem cells (PBSCs) as the graft source, outcomes actually worsened [29] owing to an increased incidence of chronic graft-versus-host disease (GVHD) [30] and associated mortality. Bone marrow is the only acceptable HSC source for patients with SAA. Additional details regarding the optimal conditioning regimen, cell dose, and posttransplant immunosuppression were recently reviewed [31] .
Reduction in the incidence of late chronic GVHD is achieved when the infused donor bone marrow cell dose (total nucleated cells corrected for peripheral white blood cell count) is limited to 2.5 Â 10 8 /kg [32] . This is most effective when infused after cyclophosphamide-200 mg/kg and horse ATG, followed by GVHD prophylaxis with CSP and methotrexate (MTX). Using this regimen for HLA-identical sibling donors, the risk of chronic GVHD is less than 10%, and the overall survival is outstanding, particularly for younger patients wherein 100% survival has been reported [33] .
In summary, a very effective conditioning regimen is the Seattle regimen of cyclophosphamide-200/horse ATG/HLA-identical sibling BMT and CSP/MTX. Tacrolimus appears to be approximately equivalent to CSP to prevent GVHD [34] . However, for older patients, the development of fludarabine (FLU)-based conditioning regimens with reduced cyclophosphamide dose has achieved good survival outcomes [35, 36] .
UNRELATED DONOR BONE MARROW TRANSPLANTATION
The outcomes after URD BMT for SAA have steadily improved over the past three decades. Bacigalupo et al. [37 & ] compared the outcome of HLA-matched URD (n ¼ 508) to sibling (n ¼ 940) HSCT in European registries between 2005 and 2009. The incidences of acute and chronic GVHD were greater for URD recipients than HLA-identical recipients, 25% and 26% versus 13% and 14%, respectively. Although the overall survival after URD was less than after HLA-identical sibling transplantation, the difference was not significant. The strongest negative predictor of survival was the use of PBSC, followed by the interval of diagnosis to transplant of at least 180 days, patient age at least 20 years, no ATG in the conditioning regimen, and positive donor/recipient cytomegalovirus status.
A prognostic risk score was developed by adding each negative predictor identified in multivariate analysis (stem cell source, interval diagnosis to transplant, age, ATG use, and CMV status). This identified low-, intermediate-and high-risk groups. With a median follow-up of 3 years, survivals were 83%, 77%, and 64%, respectively [37 & ]. In summary, PBSCs should not be used as the HSC source with HLA-matched URD transplantation. To reduce the incidence of acute and chronic GVHD, ATG should be given with the conditioning regimen. When following these guidelines, including high-resolution 10/10-HLA-allele level matching, URD BMT for SAA results in excellent overall survival, especially for age less than 20 years [37
Previously, the standard conditioning regimen for URD BMT was cyclophosphamide-200 mg/kg, horse ATG 90 mg/kg and 2 Gray (Gy) total body irradiation (TBI). However, this regimen is associated with increased risk of transplant related mortality particularly in patients age greater than 20 years [39] .
An important step in improving the outcome of URD BMT has been to reduce toxicity of the conditioning regimen by reducing the dose of cyclophosphamide and increasing the dose of FLU. A multicenter trial [38 && ] determined the optimal conditioning regimen to include: horse/rabbit ATG 30 mg/kg/day or 3 mg/kg/day, respectively, on days À4 to À2, cyclophosphamide 50 mg/kg on day À4, FLU 30 mg/m 2 /day on days À5 to À2, and 2 Gy TBI on day À1. Bone marrow was used from either 8/8-HLAmatched or 1-HLA-antigen mismatched URDs. The study compared cyclophosphamide-0, -50, -100 and -150 mg/kg. The incidence of graft failure following cyclophosphamide-0 was unacceptably high and organ toxicity following cyclophosphamide-150 was unacceptably high. Most patients received either cyclophosphamide-50 (n ¼ 38) or cyclophosphamide-100 mg/kg (n ¼ 41). However, the distribution of HLA-mismatches in the two groups was not balanced: 18% and 34% of patients in the cyclophosphamide-50 and cyclophosphamide-100 group, respectively, received 7/8 HLA-matched bone marrow. The incidence of graft failure at 1 year was 11.7% and 14.6% in the cyclophosphamide-50 and cyclophosphamide-100 groups, respectively. Of the four cyclophosphamide-50 patients with graft failure, three survived, two after second transplant. Of the six cyclophosphamide-100 patients with secondary graft failure, all died, despite second transplants. The use of HLA-mismatched grafts contributed to the increased incidence of graft failure. The incidence of acute GVHD was 23.7% and 26.8% and of chronic GVHD was 22.5% and 31.7% in the cyclophosphamide-50 and cyclophosphamide-100 groups, respectively. With a median follow-up of 17 and 24 months, the 1-year overall survival was 97.4% and 80.5% in the cyclophosphamide-50 and cyclophosphamide-100 cohorts, respectively. With longer follow-up, there were three deaths (8%) in the cyclophosphamide-50 group: one from graft failure and two from chronic GVHD. There were 10 deaths (24%) in the cyclophosphamide-100 group: six from graft failure, three from acute/chronic GVHD, and one from sepsis [38
&&
]. In summary, the combination of ATG, cyclophosphamide 50 mg/kg, FLU 120 mg/m 2 and 2 Gy TBI followed with a 10/10-HLA-allele matched URD BMT appears to be the optimal regimen and graft source. The optimal regimen for 1-HLA-antigen mismatched URD BMT is not yet defined.
Marsh et al. [36] showed that alemtuzumab (median dose 0.96 mg/kg) given in place of rabbit ATG during the conditioning regimen, combined with FLU 30 mg/m 2 /day Â 4 days and cyclophosphamide 300 mg/m 2 /day Â 4 days achieved improved overall survival following URD BMT. Fifty-five patients, median age 18 years, received HLA-matched URD transplants (19 PBSCs and 36 BM) after alemtuzumab-FLU-CY conditioning. Graft failure was observed in 9%; acute and chronic GVHD incidences were 29% and 11%, respectively, and 5-year overall survival was 88%. Bone marrow graft recipients had improved overall survival compared with PBSC recipients. This study is significant because the alemtuzumab-FLU-cyclophosphamide conditioning regimen has eliminated the use of low dose TBI for URD BMT.
Both ATG-CY50-FLU-2 Gy TBI and alemtuzumab-CY-FLU are reasonable conditioning regimens for HLA-matched URD BMT. However, the limited availability, high cost, and infectious complications associated with alemtuzumab may limit its broader use in URD BMT for SAA.
Dufour et al. [40 & ] reported on the outcome of children with acquired SAA treated with URD HSCT as first-line treatment (n ¼ 29, no IST prior to the transplant), and compared the outcome to the following three historical matched control groups: HLA-identical sibling donor BMT (n ¼ 87), IST with horse ATG and CSP (n ¼ 58), and second-line therapy with URD transplant after IST failure (n ¼ 24). The 2-year overall survival and event-free survival in each group were as follows: first-line URD HSCT: 96% and 92%, HLA-matched sibling donor BMT: 91% and 87%, first-line IST: 94% and 40%, and URD HSCT after IST failure: 74% and 74%, respectively. Others also support the recommendation to proceed with HLA-matched URD BMT as first-line therapy for children with SAA [41, 42] .
These data suggest that first-line treatment with an HLA-matched URD BMT should be strongly considered for children with acquired SAA who lack an HLA-identical sibling donor. Given the improvement in outcomes with the FLU-based conditioning regimens with low dose TBI, cyclophosphamide and ATG or alemtuzumab [36, 38 && ], and given the increased risk of failure and late complications after IST, strong consideration should also be made for young adults with SAA to proceed with definitive BMT if a 10/10-HLA-matched URD is rapidly identified. Although URD BMT can be successfully performed after IST failure or after evolution to MDS/ AML, overall survival appears to be reduced when URD BMT is used as second-line treatment.
HUMAN LEUKOCYTE ANTIGEN-HAPLOIDENTICAL FAMILY DONOR BONE MARROW TRANSPLANTATION
The successful application of posttransplant cyclophosphamide (PT-CY) conditioning for HLA-haploidentical donors has recently been reported for SAA patients. Clay et al. [43 && ] described eight patients, four with refractory SAA following IST and four with primary graft failure after URD or cord blood transplantation. The conditioning regimen was FLU 30 mg/m 2 /day days À6 to À2, cyclophosphamide 14.5 mg/kg/day (days À6 and À5) and 2 Gy TBI on day À1. HLA-haploidentical, unmanipulated, G-CSF-mobilized PBSCs were infused on day 0, followed by PT-CY 50 mg/kg/day on days þ3 and þ4. Starting on day þ5, posttransplant GVHD prophylaxis included tacrolimus for 12 months and mycophenolate mofetil (MMF) until day þ35. Six patients had sustained donor engraftment, two patients failed to engraft and subsequently died and one patient who engrafted subsequently died of multiple infectious complications. The two patients who failed to engraft had persistent, multiple antidonor HLA-antibodies. Five of the eight patients survived 3-40 months after transplant, one had successfully treated grade II skin GVHD [43 && ]. Other investigators have reported similar results with this regimen, but patients received 2-6 Gy TBI [44] .
The use of PT-CY to achieve in-vivo T-cell depletion has simplified the clinical use of HLA-haploidentical grafts and has achieved encouraging early results. It remains to be determined if bone marrow or PBSC is the preferred graft source from HLA-haploidentical donors. Currently, HLA-haploidentical grafts should be used as secondline or third-line therapy for SAA once IST has failed and if an HLA-matched URD is unavailable.
CONCLUSION
The overall survival after HSCT for SAA has improved significantly over the past few years, particularly for HLA-matched URD BMT. Survival outcomes from URD BMT are now approaching the success seen with HLA-identical sibling BMT. Recent studies with molecular sequencing of bone marrow blood cells from SAA patients treated with IST have found a large proportion of patients with clonal hematopoiesis and acquired mutations in myeloid leukemia genes. These mutations appeared early after IST and increased in frequency over time. Some of these acquired mutations confer a very high risk of progression to MDS/AML.
Given the high incidence of treatment failure with IST, the risk of evolution to MDS/AML after IST, and the improved outcomes with URD BMT, it is now reasonable to consider that younger patients with SAA should proceed to URD BMT as first-line treatment if a 10/10-HLA-matched donor is rapidly identified. With increased availability of URDs and rapid, high-resolution HLA-typing, an urgent URD search may be completed within several weeks. FLUbased conditioning regimens appear to reduce the risk of transplant related toxicity for URD BMT, especially in older patients. As with HLA-identical sibling transplantation, bone marrow is the only appropriate stem cell source from URD for first-time HSCT for SAA.
With the introduction of PT-CY conditioning regimens, HLA-haploidentical HSCT appears to be a good second-line or third-line treatment alternative for patients with refractory SAA who do not have an HLA-matched donor, particularly if patients lack antidonor HLA-antibodies. The data from small studies are encouraging, but larger multicenter studies with optimized conditioning regimens and determination of the optimal stem cell source for HLA-haploidentical HSCT are needed.
